Drug Profile
Candesartan cilexetil/rosuvastatin - Alvogen
Alternative Names: Candesartan cilexetil/rosuvastatin calcium; DP R208; Rosuvastatin/candesartanLatest Information Update: 15 Feb 2022
Price :
$50
*
At a glance
- Originator Alvogen
- Class Antihyperlipidaemics; Antihypertensives; Benzimidazoles; Fluorobenzenes; Heart failure therapies; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders; Hypertension
Most Recent Events
- 15 Feb 2022 No development reported - Phase-III for Hypertension in South Korea (PO)
- 28 Feb 2018 No recent reports of development identified for phase-I development in Cardiovascular-disorders(In volunteers) in South Korea
- 01 Oct 2016 Alvogen Korea completes a phase III trial in Hypertension in South Korea (PO) (NCT02770261)